These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

192 related items for PubMed ID: 12497205

  • 41. Clinical aspects of a phase I trial of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent.
    Jameson MB, Thompson PI, Baguley BC, Evans BD, Harvey VJ, Porter DJ, McCrystal MR, Small M, Bellenger K, Gumbrell L, Halbert GW, Kestell P, Phase I/II Trials Committee of Cancer Research UK.
    Br J Cancer; 2003 Jun 16; 88(12):1844-50. PubMed ID: 12799625
    [Abstract] [Full Text] [Related]

  • 42. Identification and reactivity of the major metabolite (beta-1-glucuronide) of the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in humans.
    Zhou SF, Paxton JW, Tingle MD, Kestell P, Jameson MB, Thompson PI, Baguley BC.
    Xenobiotica; 2001 May 16; 31(5):277-93. PubMed ID: 11491389
    [Abstract] [Full Text] [Related]

  • 43. Antivascular therapy of cancer: DMXAA.
    Baguley BC.
    Lancet Oncol; 2003 Mar 16; 4(3):141-8. PubMed ID: 12623359
    [Abstract] [Full Text] [Related]

  • 44. Phase II study of ASA404 (vadimezan, 5,6-dimethylxanthenone-4-acetic acid/DMXAA) 1800mg/m(2) combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer.
    McKeage MJ, Reck M, Jameson MB, Rosenthal MA, Gibbs D, Mainwaring PN, Freitag L, Sullivan R, Von Pawel J.
    Lung Cancer; 2009 Aug 16; 65(2):192-7. PubMed ID: 19409645
    [Abstract] [Full Text] [Related]

  • 45. Uptake of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and activation of NF-kappaB in human tumor cell lines.
    Woon ST, Baguley BC, Palmer BD, Fraser JD, Ching LM.
    Oncol Res; 2002 Aug 16; 13(2):95-101. PubMed ID: 12392157
    [Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 52. Effects of anticancer drugs on the metabolism of the anticancer drug 5,6-dimethylxanthenone-4-acetic (DMXAA) by human liver microsomes.
    Zhou S, Chin R, Kestell P, Tingle MD, Paxton JW.
    Br J Clin Pharmacol; 2001 Aug 16; 52(2):129-36. PubMed ID: 11488768
    [Abstract] [Full Text] [Related]

  • 53. Reversible binding of the novel anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid to plasma proteins and its distribution into blood cells in various species.
    Zhou S, Paxton JW, Kestell P, Tingle MD.
    J Pharm Pharmacol; 2001 Apr 16; 53(4):463-71. PubMed ID: 11341362
    [Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 56. Relationship between tumour endothelial cell apoptosis and tumour blood flow shutdown following treatment with the antivascular agent DMXAA in mice.
    Ching LM, Zwain S, Baguley BC.
    Br J Cancer; 2004 Feb 23; 90(4):906-10. PubMed ID: 14970872
    [Abstract] [Full Text] [Related]

  • 57. Stimulation of tumors to synthesize tumor necrosis factor-alpha in situ using 5,6-dimethylxanthenone-4-acetic acid: a novel approach to cancer therapy.
    Joseph WR, Cao Z, Mountjoy KG, Marshall ES, Baguley BC, Ching LM.
    Cancer Res; 1999 Feb 01; 59(3):633-8. PubMed ID: 9973211
    [Abstract] [Full Text] [Related]

  • 58.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 59.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 60.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.